Key facts
- PlasmaGen BioSciences’s last known valuation is $40.1M (Mar 2023).
- It has raised $75.0M; the latest was Later Stage VC ($16.7M) in Dec 2025.
- Notable investors include F-Prime Capital, Eight Roads, Ashish Kacholia, Anurag Bagaria, Arteqin Capital — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for PlasmaGen BioSciences
- ·The full record, as it builds
Funding rounds
No funding rounds for PlasmaGen BioSciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About PlasmaGen BioSciences
Developer of plasma protein and specialty care therapy products intended to improve treatment outcomes and patients' quality of life. The company offers biopharmaceutical products across various therapeutic areas, including neurology, hematology, oncology, immunology, pediatrics, and rheumatology, enabling healthcare organizations to address critical medical problems and conditions effectively.
- Sector
- Healthcare
- HQ
- Bangalore, India
- Founded
- 2010
- Employees
- 412
- Website
- plasmagen.com/
- Ownership
- Privately Held (backing)
PlasmaGen BioSciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in PlasmaGen BioSciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on PlasmaGen BioSciences in its N-PORT filings yet. We sweep new filings monthly.